| OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced its participation in the 21st Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today, the company showcased case studies utilizing xPloration, a high-throughput single B-cell screening platform that harnesses machine learning and computer vision artificial intelligence (AI), in a presentation by Bob Chen, Ph.D., Vice President, Discovery Systems, title. |
businesswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Q1 2025 Earnings Call Transcript |
OmniAb, Inc. (NASDAQ:OABI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matthew Foehr - Chief Executive Officer Bob Chen - Vice President, Discovery Systems Conference Call Participants Michael Almisry - Leerink Partners Alexander Xenakis - Truist Securities Joseph Pantginis - H.C. Wainwright Jacqueline Kisa - TD Cowen Operator Good afternoon, and welcome to OmniAb Inc.'s First Quarter 2025 Financial Results and Business Update Conference Call. |
seekingalpha.com |
2025-05-10 07:52:49 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates |
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2025-05-08 22:40:40 |
Czytaj oryginał (ang.) |
| OmniAb Reports First Quarter 2025 Financial Results and Business Highlights |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. “We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts,” said Matt Foehr, Chief Executive Officer of OmniAb. |
businesswire.com |
2025-05-08 20:06:00 |
Czytaj oryginał (ang.) |
| VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program |
Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors |
globenewswire.com |
2025-05-05 05:00:00 |
Czytaj oryginał (ang.) |
| OmniAb to Participate in Five Upcoming Investor Conferences |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences over the coming weeks. H.C. Wainwright 1st Annual Royalty Company Virtual Conference, May 13. Management will participate in a fireside chat and a panel discussion on Tuesday, May 13th. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors on Tuesday, May. |
businesswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| OmniAb Announces Two New Appointments to its Board of Directors |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb's partnership base. These Board changes are effective immediately and increase the number of Directo. |
businesswire.com |
2025-04-21 12:00:00 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Q4 2024 Earnings Call Transcript |
OmniAb, Inc. (NASDAQ:OABI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kripa Devarakonda - Truist Securities Operator Good afternoon and welcome to OmniAb Inc's Fourth Quarter and Full Year 2024 Financial Results and Business Update Conference call. |
seekingalpha.com |
2025-03-18 21:37:37 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates |
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago. |
zacks.com |
2025-03-18 20:25:23 |
Czytaj oryginał (ang.) |
| OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. “2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach,” said Matt Foehr, Chief Executi. |
businesswire.com |
2025-03-18 18:05:00 |
Czytaj oryginał (ang.) |
| OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss fourth quarter financial results and business updates Date: Tuesday, March 18, 2025 Time: 4:30 p.m. |
businesswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| OmniAb to Participate in Two Investor Conferences in March |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March. TD Cowen 45th Annual Health Care Conference, March 3-5 at the Boston Marriott Copley Place. Management will be presenting a corporate overview on Tuesday, March 4th at 2:30 p.m. Eastern time and will be holding one-on-one meetings with investors. 2025 Leerink Partners Global Healthcare Conference, March 9-12 at the W Hotel. |
businesswire.com |
2025-02-03 18:57:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm |
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of OmniAb, Inc. (NASDAQ: OABI) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. |
prnewswire.com |
2025-01-31 13:09:00 |
Czytaj oryginał (ang.) |
| OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego. In a presentation titled “Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,” Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from tradition. |
businesswire.com |
2024-12-16 18:15:00 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript |
OmniAb, Inc. (NASDAQ:OABI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Alex Xenakis - Truist Securities Jacqueline Kisa - TD Cowen Conor McNamara - RBC Capital Markets Operator Good afternoon, and welcome to OmniAb, Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-12 23:53:10 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates |
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.16 per share a year ago. |
zacks.com |
2024-11-12 21:10:28 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript |
OmniAb, Inc. (NASDAQ:OABI ) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President and Chief Executive Officer Conference Call Participants Michael Sonntag - Leerink Partners Chad Wiatrowski - TD Cowen Stephen Willey - Stifel Conor McNamara - RBC Capital Markets Operator Good afternoon and welcome to OmniAb Incorporated 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. |
seekingalpha.com |
2024-08-10 15:28:07 |
Czytaj oryginał (ang.) |
| Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging |
In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 2000 remains a more appropriate benchmark for comparison. Top gainers include FTAI Aviation and FTAI Infrastructure, while top detractors include Latch and Industrial Short. |
seekingalpha.com |
2024-08-06 12:25:00 |
Czytaj oryginał (ang.) |
| OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies. sdAbs are produced naturally by camelids and have gained popularity as small, robust and highly modular building blocks fo. |
businesswire.com |
2024-06-03 20:05:00 |
Czytaj oryginał (ang.) |
| OmniAb to Participate in the Jefferies Global Healthcare Conference |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors. A live and archived webcast of the presentation will be available in the Investors section of OmniAb's websit. |
businesswire.com |
2024-05-20 12:05:00 |
Czytaj oryginał (ang.) |
| OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today the Company presented an overview of xPloration, a high-throughput single B-cell screening platform that leverages machine learning and Artificial Intelligence (AI), in a presentation titled “Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibod. |
businesswire.com |
2024-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Q1 2024 Earnings Call Transcript |
OmniAb, Inc. (NASDAQ:OABI ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Nishant Gandhi - Truist Securities Jack Siedow - Craig-Hallum Michael Sonntag - Leerink Partners Jacqueline Kisa - Cowen Operator Good afternoon and welcome to OmniAb Inc. First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-10 20:33:10 |
Czytaj oryginał (ang.) |
| OmniAb Reports First Quarter 2024 Financial Results and Business Highlights |
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base. We added three new platform license agreements in the first quarter, bringing our total active partners to 80, net of attrition,” said Matt Foehr, Chief Executive Officer of O. |
businesswire.com |
2024-05-09 20:05:00 |
Czytaj oryginał (ang.) |
| OmniAb to Participate in Five Investor Conferences in May |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences during the month of May. RBC Capital Markets Global Healthcare Conference, May 14-15 at the InterContinental Barclay Hotel in New York City. Management will participate in a fireside chat on Wednesday, May 15th at 11:30 a.m. Eastern time and will hold one-on-one meetings with investors. A live and archived webcast of the fireside chat will be availa. |
businesswire.com |
2024-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| OmniAb to Report First Quarter 2024 Financial Results on May 9 |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss financial results and business updates Date: Thursday, May 9, 2024 Time: 4:30 p.m. Eastern time (1:30 p.m. Pac. |
businesswire.com |
2024-04-22 12:00:00 |
Czytaj oryginał (ang.) |
| Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics |
Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation BRIDGEWATER, NJ / ACCESSWIRE / April 15, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced today the formation of a new Scientific Advisory Board (SAB) that includes a group of leading experts in fields spanning immunology, liver disease clinical trials, protein engineering, antibody drug conjugates as well as Knob domains, the smallest antibody like fragments. "Tharimmune's mission is to advance immunology and oncology treatments for people suffering from high unmet need conditions and help them look forward to a better tomorrow," said Randy Milby, Chief Executive Officer of Tharimmune. |
accesswire.com |
2024-04-15 12:31:00 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript |
OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-20 21:38:04 |
Czytaj oryginał (ang.) |
| OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates. “2023 was a year of significant expansion of OmniAb's partnership base and pipeline programs as we continued to execute against our plan, while key partner programs made significant progress despite last year's sector-related headwinds. Partners exceeded our expectations regarding the number of. |
businesswire.com |
2024-03-20 18:05:00 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? |
OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-02-28 11:31:20 |
Czytaj oryginał (ang.) |
| OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss financial results and business updates Date: Wednesday, March 20, 2024 Time: 4:30 p.m. Eastern t. |
businesswire.com |
2024-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| Mighty Minis: 7 Small-Cap Stocks That Punch Above Their Weight |
While your typical financial advisor will likely direct you to focus on established blue chips to boost your holdings, few other compelling options exist other than powerful small-cap stocks. To be 100% clear, entities that offer significant upside reward potential usually carry significant risks. |
investorplace.com |
2023-12-15 10:50:39 |
Czytaj oryginał (ang.) |
| OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference |
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry's first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society. The Company presented an overview of OmnidAb and its functionality to industry leaders and prospective customers today in a presenta. |
businesswire.com |
2023-12-14 18:30:00 |
Czytaj oryginał (ang.) |
| OmniAb, Inc. (OABI) Research and Technology Virtual Event and Q3 2023 Earnings Call Transcript |
OmniAb, Inc. (NASDAQ:OABI ) Research & Technology Virtual Event and 3Q23 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Matthew Foehr - President and CEO Todd Pettingill - VP, Business Development and Strategy Bill Harriman - SVP, Antibody Discovery Bob Chen - Senior Director, Discovery Systems Doug Krafte - SVP, Ion Channels Kurt Gustafson - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright & Co. Puneet Souda - Leerink Partners Stephen Willey - Stifel Nishant Gandhi - Truist Securities Matthew Foehr Okay, great, we're at 8 am Pacific Time, 11 am Eastern time. |
seekingalpha.com |
2023-11-14 14:44:09 |
Czytaj oryginał (ang.) |